Intravenous Therapy
Nasal spray form of bumetanide may be just as good as oral, IV
CHICAGO — A novel nasal spray formulation of bumetanide, a commonly used diuretic for patients with HF, had similar safety, tolerability, relative bioavailability and pharmacodynamics to the oral and IV versions, researchers reported.
IV administration of fasudil safe, well tolerated in ALS
IV administration of fasudil at two separate doses was safe and well tolerated in a small cohort of individuals with suspected or confirmed ALS, according to new research published in The Lancet.
IV adrenomedullin shows favorable safety profile within 24 hours of acute ischemic stroke
Intravenous adrenomedullin given to individuals within 24 hours of acute ischemic stroke was found to be safe at 90 days, according to a presentation from the International Stroke Conference.
‘Oral is the new IV’: Another treatment dogma bites the dust?
A lot of modern medicine is based on what Brad Spellberg, MD, and others call “inertial dogmas” — practices traced to decades-old evidence that are no longer supported by modern studies.
FDA clears updated Alaris infusion pump; recall remediation remains ‘top priority’
The FDA granted 510(k) clearance to Becton Dickinson’s updated Alaris infusion pump, allowing the company to resume distribution of its system while remediating or replacing older Alaris devices still being used in the U.S. market.
Outpatient IV ketamine therapy could improve pain in refractory chronic migraine
AUSTIN, Texas — In-clinic administration of IV ketamine significantly improved refractory chronic migraine pain intensity in a small cohort of patients, according to a poster presented here.
IV iron therapy may not improve exercise ability in patients with CKD
Intravenous iron therapy did not improve exercise capacity in nonanemic patients with iron deficiency who have chronic kidney disease, according to recently published data.
Tenecteplase not associated with better outcome at 90 days in those with wake-up stroke
Treatment with IV Tenecteplase was not associated with better functional outcome after 90 days in patients with wake-up stroke selected using advanced imaging, per a study published in The Lancet Neurology.
Early initiation of prostanoid therapy yields favorable outcome in children with PAH
In children with pulmonary arterial hypertension, early initiation of IV or subcutaneous parenteral prostanoid therapy, higher doses of therapy and when combined with additional PAH therapy were associated with favorable outcomes.